Market Place
Sourcing Support
Phase III Trial for Chiauranib in Small Cell Lung Cancer Approved
01 Nov 2024 //
PR NEWSWIRE
Chipscreen`s CS231295 Tablets IND Application Accepted
17 Oct 2024 //
PR NEWSWIRE
Chiglitazar Selected For Oral Presentation At Liver Disease Meeting
15 Oct 2024 //
PR NEWSWIRE
NMPA Approves Chidamide+R-CHOP For Diffuse Large B-Cell Lymphoma
30 Apr 2024 //
PR NEWSWIRE
Positive results from Phase II clinical trial of Chiglitazar monotherapy
18 Mar 2024 //
PR NEWSWIRE
Chipscreen`s New Drug Candidate CS32582 Capsules Approved for Psoriasis
02 Nov 2023 //
PR NEWSWIRE
Chipscreen bags Chinese rights to Biocytogen`s Keytruda killer
27 Feb 2023 //
FIERCE BIOTECH
Chipscreen Biosciences Announces NMPA New Drug Approval of Bilessglu®
19 Oct 2021 //
PRNEWSWIRE
Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND
16 Apr 2021 //
BIOSPACE
Chipscreen and HISUN reach a strategic cooperation
16 Dec 2020 //
PRNEWSWIRE
Chipscreen and HISUN reach a strategic cooperation
16 Dec 2020 //
PRNEWSWIRE
Chipscreen Biosciences`s Original New Drug CS12192: (IND) Application Accepted
24 Mar 2020 //
PR NEWSWIRE
NMPA Approves Chipscreen Bioscience`s Chidamide for Breast Cancer Indication
30 Nov 2019 //
PR NEWSWIRE
Chipscreen Biosciences`s Oringinal New Drug Bilessglu® (for Type 2 Diabetes)
19 Sep 2019 //
PRNASIA
Move over, Hong Kong: Shanghai’s new tech board sees fervent demand
02 Aug 2019 //
ENDPTS
Chipscreen sets pace for biotech IPOs in Shanghai
31 Jul 2019 //
BIOCENTURY
Chipscreen Announces a Collaboration with Innovent to Evaluate Chidamide
18 Feb 2019 //
PRNASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.